Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCM/EADO 2021 | Real-world analysis of T-VEC for melanoma

Alexander van Akkooi, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, gives an overview of a retrospective analysis which explored the real-world use of talimogene laherparepvec (T-VEC), an oncolytic virus, in unresectable melanoma. Dr van Akkooi outlines the findings of the study, comparing patterns of use of T-VEC in different countries. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.

Disclosures

Alexander van Akkooi, MD, PhD, discloses links to Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Sirius Medical and 4SC.